1 – 10 of 12
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2007
- Congo red and protein aggregation in neurodegenerative diseases
- Decreased VIP and VPAC(2) receptor expression in the biological clock of the R6/2 Huntington's disease mouse
- 2006
- Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases.
- Verapamil prevents, in a dose-dependent way, the loss of ChAT-immunoreactive neurons in the cerebral cortex following lesions of the rat nucleus basalis magnocellularis
- 2005
- Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes.
-
Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease.
Papalexi, Eugenia LU ; Persson, Anna ; Björkqvist, Maria LU ; Petersén, Åsa LU ; Woodman, Ben ; Bates, Gillian P ; Sundler, Frank LU ; Mulder, Hindrik LU
; Brundin, Patrik
LU
and Popovic, Natalija
LU
(2005)
In European Journal of Neuroscience
22(6).
p.1541-1546
Mark
- Orexin loss in Huntington's disease.
- Reduced hippocampal neurogenesis in R6/2 transgenic Huntington's disease mice.
-
The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient {beta}-cell mass and exocytosis.
Björkqvist, Maria LU ; Fex, Malin LU ; Renström, Erik LU ; Wierup, Nils LU ; Petersén, Åsa LU ; Gil, Joana LU ; Bacos, Karl LU
; Popovic, Natalija
LU
; Li, Jia-Yi
LU
and Sundler, Frank
LU
, et al.
(2005)
In Human Molecular Genetics
14(5).
p.565-574
Mark
- The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.